”Following completion of the 21-day observation period at 3.4 mg/kg (Cohort 9), no dose limiting toxicities (DLTs) or serious adverse events (SAEs) were observed
Two patients in Cohort 9 experienced rapid PSA reduction at three weeks post-treatment following the first ARX517 dose”
CAR T-Cell Use Possible in Metastatic Castration-Resistant Prostate Cancer
more possibilities after exhausting SOC?: Enzalutamide-resistant castration-resistant prostate cancer: challenges and solutions
Treatment options for metastatic prostate cancer? 
Real-World Comparison of Cabazitaxel Versus 177Lu-PSMA Radiopharmaceutical Therapy in Metastatic Castration-Resistant Prostate Cancer
Androgen Cycling Shows Promise in Castration-Resistant Prostate Cancer
